Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMBULELO phase II trial of VRC07-523LS in breastfed HIV-exposed and HIV-infected infants
PACTR202308483453792Phase 2Recruiting
- Sponsor
- South African Medical Research Council
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VRC07-523LS in human immunodeficiency virus infection (HIV) (4 arms), sponsored by South African Medical Research Council. Primary endpoint: Serious adverse events in group 1. Started Feb 2023; status: recruiting.
02
Drugs
VRC07-523LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202308483453792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202308483453792.